Traws Pharma (NASDAQ:TRAW) Shares Down 1.4% – Should You Sell?

Traws Pharma, Inc. (NASDAQ:TRAW) was down 1.4% during trading on Monday . The company traded as low as $1.35 and last traded at $1.40. Approximately 45,825 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 146,839 shares. The stock had previously closed at $1.42.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Traws Pharma to a “hold” rating in a research report on Friday, June 27th.

Traws Pharma Price Performance

The business has a 50 day simple moving average of $1.51 and a 200 day simple moving average of $1.92. The company has a market capitalization of $9.88 million, a price-to-earnings ratio of 0.02 and a beta of 1.52.

Traws Pharma (NASDAQ:TRAW) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($8.75) by $8.64. Traws Pharma had a negative return on equity of 1,812.48% and a net margin of 3,028.25%.The company had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $0.06 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new position in Traws Pharma during the fourth quarter worth $89,000. Renaissance Technologies LLC acquired a new stake in shares of Traws Pharma in the fourth quarter valued at $89,000. Alyeska Investment Group L.P. acquired a new stake in shares of Traws Pharma in the fourth quarter valued at $1,036,000. Vestal Point Capital LP acquired a new stake in shares of Traws Pharma in the fourth quarter valued at $666,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Traws Pharma in the first quarter valued at $759,000. 7.95% of the stock is currently owned by institutional investors and hedge funds.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.